|
Acute respiratory failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to examine the efficacy of PMX-DHP therapy for acute respiratory failure in patients with RPIPs, when compared with a historical control receiving conventional treatment without PMX-DHP.
|
28554260 |
2017 |
|
Adult Fibrosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Moreover, we have established that increasing the length of the alkyl chain at the quaternised nitrogen of the 4-(<i>N</i>-alkylpyridinium)-1,4-DHP molecule or the introduction of propargyl moieties in the 1,4-DHP molecule significantly influences the cytotoxicity on HT-1080 (human fibrosarcoma) and MH-22A (mouse hepatocarcinoma) cell lines, as well as the estimated basal cytotoxicity.
|
30871041 |
2019 |
|
Adult Liver Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Overall, this study emphasizes the possible potential and therapeutic role of DHP-8 in skin and liver cancer.
|
30203236 |
2018 |
|
Anus, Imperforate
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Bipolar Disorder
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Genetic linkage studies associate tubulin-binding proteins such as the dihydropyrimidinase family with an increased risk to develop schizophrenia and bipolar disorder.
|
27112918 |
2016 |
|
Brain atrophy
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Here, we show that 4 newly identified DHP deficient patients presented with strongly elevated levels of 5,6-dihydrouracil and 5,6-dihydrothymine in urine and a highly variable clinical presentation, ranging from asymptomatic to infantile spasm and reduced white matter and brain atrophy.
|
29054612 |
2017 |
|
Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Finally, SLC16A12, GALR2, TOX, SPOCK2, EGFR5 and DPYS are candidate biomarkers for breast cancer (methylation range 33%-79%) with the combination of EGFR5 or TOX hypermethylation showing a sensitivity of 92% and specificity of 92%.
|
18446232 |
2008 |
|
Central neuroblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Dihydropyrimidinase-like protein 3 expression is negatively regulated by MYCN and associated with clinical outcome in neuroblastoma.
|
24011394 |
2013 |
|
Cerebral atrophy
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Here, we show that 4 newly identified DHP deficient patients presented with strongly elevated levels of 5,6-dihydrouracil and 5,6-dihydrothymine in urine and a highly variable clinical presentation, ranging from asymptomatic to infantile spasm and reduced white matter and brain atrophy.
|
29054612 |
2017 |
|
Childhood Neuroblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Dihydropyrimidinase-like protein 3 expression is negatively regulated by MYCN and associated with clinical outcome in neuroblastoma.
|
24011394 |
2013 |
|
Colon Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Similarly NKX2-5, SPOCK2, SLC16A12, DPYS and GALR2 are candidate biomarkers for colon cancer (methylation range 60%-95%) and GALR2 hypermethylation showed a sensitivity of 85% and specificity of 95%.
|
18446232 |
2008 |
|
Colon Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
We performed genetic analyses of the family of a patient with advanced colon cancer who underwent radical colectomy followed by treatment with 5-FU prodrug capecitabine and developed severe toxicity attributable to a lack of DHP.
|
25915935 |
2015 |
|
Congenital Abnormality
|
0.010 |
Biomarker
|
group |
BEFREE |
The only calcium channel mutation reported to date is a deletion in the gene for the DHP-receptor alpha 1-subunit resulting in neonatal death in muscular dysgenesis mice (1).
|
7987325 |
1994 |
|
Congenital clubfoot
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Delayed speech and language development
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Diabetes
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The Diabetes Health Profile-18 (DHP-18) was developed to measure disease-specific health-related quality of life.
|
30613400 |
2018 |
|
Diabetes
|
0.020 |
Biomarker
|
disease |
BEFREE |
Developing preference-based measures for diabetes: DHP-3D and DHP-5D.
|
28477411 |
2017 |
|
Diabetes Mellitus
|
0.020 |
Biomarker
|
group |
BEFREE |
Developing preference-based measures for diabetes: DHP-3D and DHP-5D.
|
28477411 |
2017 |
|
Diabetes Mellitus
|
0.020 |
GeneticVariation
|
group |
BEFREE |
The Diabetes Health Profile-18 (DHP-18) was developed to measure disease-specific health-related quality of life.
|
30613400 |
2018 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.010 |
Biomarker
|
disease |
BEFREE |
Psychometric testing of the Norwegian Diabetes Health Profile (DHP-18) in patients with type 1 diabetes.
|
30613400 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.010 |
Biomarker
|
disease |
BEFREE |
Using DHP, a larger negative impact related to type 2 diabetes mellitus is found in those with lower educational level, female and younger (20-39 years) or older (60-79 years) subjects.
|
30799197 |
2019 |
|
Diabetic Nephropathy
|
0.010 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> Non-DHP CCBs may be a reasonable therapeutic option for patients with diabetic kidney disease and persistent proteinuria despite maximum doses of ACE inhibitors or ARBs.
|
30966785 |
2019 |
|
Dihydropyrimidinase deficiency
|
0.710 |
GeneticVariation
|
disease |
CLINVAR |
Functional characterization of 21 allelic variants of dihydropyrimidinase.
|
28642038 |
2017 |
|
Dihydropyrimidinase deficiency
|
0.710 |
GeneticVariation
|
disease |
BEFREE |
Dihydropyrimidinase deficiency in four East Asian patients due to novel and rare DPYS mutations affecting protein structural integrity and catalytic activity.
|
29054612 |
2017 |
|
Dihydropyrimidinase deficiency
|
0.710 |
CausalMutation
|
disease |
CLINVAR |
|
|
|